BCL2 and acute myeloid leukemia: We further showed that a low p42/p30 ratio reduces the sensitivity of AML cells to the BCL2 inhibitor venetoclax, suggesting that AML patients with a low C/EBPα p42/p30 ratio (e.g., CEBPAbi) may not benefit from monotherapy using venetoclax.